1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Hepatoma Cell Targeted Drug Market Size Growth Rate by Type: 2017 VS 2021 VS 2028 1.2.2 Sorafenib 1.2.3 Lenvatinib 1.2.4 Regorafenib 1.2.5 Other 1.3 Market by Application 1.3.1 Global Hepatoma Cell Targeted Drug Market Share by Application: 2017 VS 2021 VS 2028 1.3.2 Hospital 1.3.3 Retail Pharmacy 1.3.4 Other 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global Hepatoma Cell Targeted Drug Market Perspective (2017-2028) 2.2 Hepatoma Cell Targeted Drug Growth Trends by Region 2.2.1 Hepatoma Cell Targeted Drug Market Size by Region: 2017 VS 2021 VS 2028 2.2.2 Hepatoma Cell Targeted Drug Historic Market Size by Region (2017-2022) 2.2.3 Hepatoma Cell Targeted Drug Forecasted Market Size by Region (2023-2028) 2.3 Hepatoma Cell Targeted Drug Market Dynamics 2.3.1 Hepatoma Cell Targeted Drug Industry Trends 2.3.2 Hepatoma Cell Targeted Drug Market Drivers 2.3.3 Hepatoma Cell Targeted Drug Market Challenges 2.3.4 Hepatoma Cell Targeted Drug Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Hepatoma Cell Targeted Drug Players by Revenue 3.1.1 Global Top Hepatoma Cell Targeted Drug Players by Revenue (2017-2022) 3.1.2 Global Hepatoma Cell Targeted Drug Revenue Market Share by Players (2017-2022) 3.2 Global Hepatoma Cell Targeted Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Players Covered: Ranking by Hepatoma Cell Targeted Drug Revenue 3.4 Global Hepatoma Cell Targeted Drug Market Concentration Ratio 3.4.1 Global Hepatoma Cell Targeted Drug Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Hepatoma Cell Targeted Drug Revenue in 2021 3.5 Hepatoma Cell Targeted Drug Key Players Head office and Area Served 3.6 Key Players Hepatoma Cell Targeted Drug Product Solution and Service 3.7 Date of Enter into Hepatoma Cell Targeted Drug Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Hepatoma Cell Targeted Drug Breakdown Data by Type 4.1 Global Hepatoma Cell Targeted Drug Historic Market Size by Type (2017-2022) 4.2 Global Hepatoma Cell Targeted Drug Forecasted Market Size by Type (2023-2028) 5 Hepatoma Cell Targeted Drug Breakdown Data by Application 5.1 Global Hepatoma Cell Targeted Drug Historic Market Size by Application (2017-2022) 5.2 Global Hepatoma Cell Targeted Drug Forecasted Market Size by Application (2023-2028) 6 North America 6.1 North America Hepatoma Cell Targeted Drug Market Size (2017-2028) 6.2 North America Hepatoma Cell Targeted Drug Market Size by Country (2017-2022) 6.3 North America Hepatoma Cell Targeted Drug Market Size by Country (2023-2028) 6.4 United States 6.5 Canada 7 Europe 7.1 Europe Hepatoma Cell Targeted Drug Market Size (2017-2028) 7.2 Europe Hepatoma Cell Targeted Drug Market Size by Country (2017-2022) 7.3 Europe Hepatoma Cell Targeted Drug Market Size by Country (2023-2028) 7.4 Germany 7.5 France 7.6 U.K. 7.7 Italy 7.8 Russia 7.9 Nordic Countries 8 Asia-Pacific 8.1 Asia-Pacific Hepatoma Cell Targeted Drug Market Size (2017-2028) 8.2 Asia-Pacific Hepatoma Cell Targeted Drug Market Size by Country (2017-2022) 8.3 Asia-Pacific Hepatoma Cell Targeted Drug Market Size by Country (2023-2028) 8.4 China 8.5 Japan 8.6 South Korea 8.7 Southeast Asia 8.8 India 8.9 Australia 9 Latin America 9.1 Latin America Hepatoma Cell Targeted Drug Market Size (2017-2028) 9.2 Latin America Hepatoma Cell Targeted Drug Market Size by Country (2017-2022) 9.3 Latin America Hepatoma Cell Targeted Drug Market Size by Country (2023-2028) 9.4 Mexico 9.5 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Hepatoma Cell Targeted Drug Market Size (2017-2028) 10.2 Middle East & Africa Hepatoma Cell Targeted Drug Market Size by Country (2017-2022) 10.3 Middle East & Africa Hepatoma Cell Targeted Drug Market Size by Country (2023-2028) 10.4 Turkey 10.5 Saudi Arabia 10.6 UAE 11 Key Players Profiles 11.1 Bayer 11.1.1 Bayer Company Detail 11.1.2 Bayer Business Overview 11.1.3 Bayer Hepatoma Cell Targeted Drug Introduction 11.1.4 Bayer Revenue in Hepatoma Cell Targeted Drug Business (2017-2022) 11.1.5 Bayer Recent Development 11.2 Eisai 11.2.1 Eisai Company Detail 11.2.2 Eisai Business Overview 11.2.3 Eisai Hepatoma Cell Targeted Drug Introduction 11.2.4 Eisai Revenue in Hepatoma Cell Targeted Drug Business (2017-2022) 11.2.5 Eisai Recent Development 11.3 Zelgen 11.3.1 Zelgen Company Detail 11.3.2 Zelgen Business Overview 11.3.3 Zelgen Hepatoma Cell Targeted Drug Introduction 11.3.4 Zelgen Revenue in Hepatoma Cell Targeted Drug Business (2017-2022) 11.3.5 Zelgen Recent Development 11.4 Cipla 11.4.1 Cipla Company Detail 11.4.2 Cipla Business Overview 11.4.3 Cipla Hepatoma Cell Targeted Drug Introduction 11.4.4 Cipla Revenue in Hepatoma Cell Targeted Drug Business (2017-2022) 11.4.5 Cipla Recent Development 11.5 Natco Pharma 11.5.1 Natco Pharma Company Detail 11.5.2 Natco Pharma Business Overview 11.5.3 Natco Pharma Hepatoma Cell Targeted Drug Introduction 11.5.4 Natco Pharma Revenue in Hepatoma Cell Targeted Drug Business (2017-2022) 11.5.5 Natco Pharma Recent Development 11.6 BEACON Pharma 11.6.1 BEACON Pharma Company Detail 11.6.2 BEACON Pharma Business Overview 11.6.3 BEACON Pharma Hepatoma Cell Targeted Drug Introduction 11.6.4 BEACON Pharma Revenue in Hepatoma Cell Targeted Drug Business (2017-2022) 11.6.5 BEACON Pharma Recent Development 11.7 Jiangxi Shanxiang 11.7.1 Jiangxi Shanxiang Company Detail 11.7.2 Jiangxi Shanxiang Business Overview 11.7.3 Jiangxi Shanxiang Hepatoma Cell Targeted Drug Introduction 11.7.4 Jiangxi Shanxiang Revenue in Hepatoma Cell Targeted Drug Business (2017-2022) 11.7.5 Jiangxi Shanxiang Recent Development 11.8 Yao Pharma 11.8.1 Yao Pharma Company Detail 11.8.2 Yao Pharma Business Overview 11.8.3 Yao Pharma Hepatoma Cell Targeted Drug Introduction 11.8.4 Yao Pharma Revenue in Hepatoma Cell Targeted Drug Business (2017-2022) 11.8.5 Yao Pharma Recent Development 11.9 CSPC 11.9.1 CSPC Company Detail 11.9.2 CSPC Business Overview 11.9.3 CSPC Hepatoma Cell Targeted Drug Introduction 11.9.4 CSPC Revenue in Hepatoma Cell Targeted Drug Business (2017-2022) 11.9.5 CSPC Recent Development 11.10 CHIATAI Tianqing 11.10.1 CHIATAI Tianqing Company Detail 11.10.2 CHIATAI Tianqing Business Overview 11.10.3 CHIATAI Tianqing Hepatoma Cell Targeted Drug Introduction 11.10.4 CHIATAI Tianqing Revenue in Hepatoma Cell Targeted Drug Business (2017-2022) 11.10.5 CHIATAI Tianqing Recent Development 11.11 Simcere 11.11.1 Simcere Company Detail 11.11.2 Simcere Business Overview 11.11.3 Simcere Hepatoma Cell Targeted Drug Introduction 11.11.4 Simcere Revenue in Hepatoma Cell Targeted Drug Business (2017-2022) 11.11.5 Simcere Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Global Hepatoma Cell Targeted Drug Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028 Table 2. Key Players of Sorafenib Table 3. Key Players of Lenvatinib Table 4. Key Players of Regorafenib Table 5. Key Players of Other Table 6. Global Hepatoma Cell Targeted Drug Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028 Table 7. Global Hepatoma Cell Targeted Drug Market Size by Region (US$ Million): 2017 VS 2021 VS 2028 Table 8. Global Hepatoma Cell Targeted Drug Market Size by Region (2017-2022) & (US$ Million) Table 9. Global Hepatoma Cell Targeted Drug Market Share by Region (2017-2022) Table 10. Global Hepatoma Cell Targeted Drug Forecasted Market Size by Region (2023-2028) & (US$ Million) Table 11. Global Hepatoma Cell Targeted Drug Market Share by Region (2023-2028) Table 12. Hepatoma Cell Targeted Drug Market Trends Table 13. Hepatoma Cell Targeted Drug Market Drivers Table 14. Hepatoma Cell Targeted Drug Market Challenges Table 15. Hepatoma Cell Targeted Drug Market Restraints Table 16. Global Hepatoma Cell Targeted Drug Revenue by Players (2017-2022) & (US$ Million) Table 17. Global Hepatoma Cell Targeted Drug Market Share by Players (2017-2022) Table 18. Global Top Hepatoma Cell Targeted Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hepatoma Cell Targeted Drug as of 2021) Table 19. Ranking of Global Top Hepatoma Cell Targeted Drug Companies by Revenue (US$ Million) in 2021 Table 20. Global 5 Largest Players Market Share by Hepatoma Cell Targeted Drug Revenue (CR5 and HHI) & (2017-2022) Table 21. Key Players Headquarters and Area Served Table 22. Key Players Hepatoma Cell Targeted Drug Product Solution and Service Table 23. Date of Enter into Hepatoma Cell Targeted Drug Market Table 24. Mergers & Acquisitions, Expansion Plans Table 25. Global Hepatoma Cell Targeted Drug Market Size by Type (2017-2022) & (US$ Million) Table 26. Global Hepatoma Cell Targeted Drug Revenue Market Share by Type (2017-2022) Table 27. Global Hepatoma Cell Targeted Drug Forecasted Market Size by Type (2023-2028) & (US$ Million) Table 28. Global Hepatoma Cell Targeted Drug Revenue Market Share by Type (2023-2028) Table 29. Global Hepatoma Cell Targeted Drug Market Size by Application (2017-2022) & (US$ Million) Table 30. Global Hepatoma Cell Targeted Drug Revenue Market Share by Application (2017-2022) Table 31. Global Hepatoma Cell Targeted Drug Forecasted Market Size by Application (2023-2028) & (US$ Million) Table 32. Global Hepatoma Cell Targeted Drug Revenue Market Share by Application (2023-2028) Table 33. North America Hepatoma Cell Targeted Drug Market Size by Country (2017-2022) & (US$ Million) Table 34. North America Hepatoma Cell Targeted Drug Market Size by Country (2023-2028) & (US$ Million) Table 35. Europe Hepatoma Cell Targeted Drug Market Size by Country (2017-2022) & (US$ Million) Table 36. Europe Hepatoma Cell Targeted Drug Market Size by Country (2023-2028) & (US$ Million) Table 37. Asia-Pacific Hepatoma Cell Targeted Drug Market Size by Region (2017-2022) & (US$ Million) Table 38. Asia-Pacific Hepatoma Cell Targeted Drug Market Size by Region (2023-2028) & (US$ Million) Table 39. Latin America Hepatoma Cell Targeted Drug Market Size by Country (2017-2022) & (US$ Million) Table 40. Latin America Hepatoma Cell Targeted Drug Market Size by Country (2023-2028) & (US$ Million) Table 41. Middle East & Africa Hepatoma Cell Targeted Drug Market Size by Country (2017-2022) & (US$ Million) Table 42. Middle East & Africa Hepatoma Cell Targeted Drug Market Size by Country (2023-2028) & (US$ Million) Table 43. Bayer Company Detail Table 44. Bayer Business Overview Table 45. Bayer Hepatoma Cell Targeted Drug Product Table 46. Bayer Revenue in Hepatoma Cell Targeted Drug Business (2017-2022) & (US$ Million) Table 47. Bayer Recent Development Table 48. Eisai Company Detail Table 49. Eisai Business Overview Table 50. Eisai Hepatoma Cell Targeted Drug Product Table 51. Eisai Revenue in Hepatoma Cell Targeted Drug Business (2017-2022) & (US$ Million) Table 52. Eisai Recent Development Table 53. Zelgen Company Detail Table 54. Zelgen Business Overview Table 55. Zelgen Hepatoma Cell Targeted Drug Product Table 56. Zelgen Revenue in Hepatoma Cell Targeted Drug Business (2017-2022) & (US$ Million) Table 57. Zelgen Recent Development Table 58. Cipla Company Detail Table 59. Cipla Business Overview Table 60. Cipla Hepatoma Cell Targeted Drug Product Table 61. Cipla Revenue in Hepatoma Cell Targeted Drug Business (2017-2022) & (US$ Million) Table 62. Cipla Recent Development Table 63. Natco Pharma Company Detail Table 64. Natco Pharma Business Overview Table 65. Natco Pharma Hepatoma Cell Targeted Drug Product Table 66. Natco Pharma Revenue in Hepatoma Cell Targeted Drug Business (2017-2022) & (US$ Million) Table 67. Natco Pharma Recent Development Table 68. BEACON Pharma Company Detail Table 69. BEACON Pharma Business Overview Table 70. BEACON Pharma Hepatoma Cell Targeted Drug Product Table 71. BEACON Pharma Revenue in Hepatoma Cell Targeted Drug Business (2017-2022) & (US$ Million) Table 72. BEACON Pharma Recent Development Table 73. Jiangxi Shanxiang Company Detail Table 74. Jiangxi Shanxiang Business Overview Table 75. Jiangxi Shanxiang Hepatoma Cell Targeted Drug Product Table 76. Jiangxi Shanxiang Revenue in Hepatoma Cell Targeted Drug Business (2017-2022) & (US$ Million) Table 77. Jiangxi Shanxiang Recent Development Table 78. Yao Pharma Company Detail Table 79. Yao Pharma Business Overview Table 80. Yao Pharma Hepatoma Cell Targeted Drug Product Table 81. Yao Pharma Revenue in Hepatoma Cell Targeted Drug Business (2017-2022) & (US$ Million) Table 82. Yao Pharma Recent Development Table 83. CSPC Company Detail Table 84. CSPC Business Overview Table 85. CSPC Hepatoma Cell Targeted Drug Product Table 86. CSPC Revenue in Hepatoma Cell Targeted Drug Business (2017-2022) & (US$ Million) Table 87. CSPC Recent Development Table 88. CHIATAI Tianqing Company Detail Table 89. CHIATAI Tianqing Business Overview Table 90. CHIATAI Tianqing Hepatoma Cell Targeted Drug Product Table 91. CHIATAI Tianqing Revenue in Hepatoma Cell Targeted Drug Business (2017-2022) & (US$ Million) Table 92. CHIATAI Tianqing Recent Development Table 93. Simcere Company Detail Table 94. Simcere Business Overview Table 95. Simcere Hepatoma Cell Targeted DrugProduct Table 96. Simcere Revenue in Hepatoma Cell Targeted Drug Business (2017-2022) & (US$ Million) Table 97. Simcere Recent Development Table 98. Research Programs/Design for This Report Table 99. Key Data Information from Secondary Sources Table 100. Key Data Information from Primary Sources List of Figures Figure 1. Global Hepatoma Cell Targeted Drug Market Share by Type: 2021 VS 2028 Figure 2. Sorafenib Features Figure 3. Lenvatinib Features Figure 4. Regorafenib Features Figure 5. Other Features Figure 6. Global Hepatoma Cell Targeted Drug Market Share by Application in 2021 & 2028 Figure 7. Hospital Case Studies Figure 8. Retail Pharmacy Case Studies Figure 9. Other Case Studies Figure 10. Hepatoma Cell Targeted Drug Report Years Considered Figure 11. Global Hepatoma Cell Targeted Drug Market Size (US$ Million), Year-over-Year: 2017-2028 Figure 12. Global Hepatoma Cell Targeted Drug Market Size, (US$ Million), 2017 VS 2021 VS 2028 Figure 13. Global Hepatoma Cell Targeted Drug Market Share by Region: 2021 VS 2028 Figure 14. Global Hepatoma Cell Targeted Drug Market Share by Players in 2021 Figure 15. Global Top Hepatoma Cell Targeted Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hepatoma Cell Targeted Drug as of 2021) Figure 16. The Top 10 and 5 Players Market Share by Hepatoma Cell Targeted Drug Revenue in 2021 Figure 17. North America Hepatoma Cell Targeted Drug Market Size YoY Growth (2017-2028) & (US$ Million) Figure 18. North America Hepatoma Cell Targeted Drug Market Share by Country (2017-2028) Figure 19. United States Hepatoma Cell Targeted Drug Market Size YoY Growth (2017-2028) & (US$ Million) Figure 20. Canada Hepatoma Cell Targeted Drug Market Size YoY Growth (2017-2028) & (US$ Million) Figure 21. Europe Hepatoma Cell Targeted Drug Market Size YoY Growth (2017-2028) & (US$ Million) Figure 22. Europe Hepatoma Cell Targeted Drug Market Share by Country (2017-2028) Figure 23. Germany Hepatoma Cell Targeted Drug Market Size YoY Growth (2017-2028) & (US$ Million) Figure 24. France Hepatoma Cell Targeted Drug Market Size YoY Growth (2017-2028) & (US$ Million) Figure 25. U.K. Hepatoma Cell Targeted Drug Market Size YoY Growth (2017-2028) & (US$ Million) Figure 26. Italy Hepatoma Cell Targeted Drug Market Size YoY Growth (2017-2028) & (US$ Million) Figure 27. Russia Hepatoma Cell Targeted Drug Market Size YoY Growth (2017-2028) & (US$ Million) Figure 28. Nordic Countries Hepatoma Cell Targeted Drug Market Size YoY Growth (2017-2028) & (US$ Million) Figure 29. Asia-Pacific Hepatoma Cell Targeted Drug Market Size YoY Growth (2017-2028) & (US$ Million) Figure 30. Asia-Pacific Hepatoma Cell Targeted Drug Market Share by Region (2017-2028) Figure 31. China Hepatoma Cell Targeted Drug Market Size YoY Growth (2017-2028) & (US$ Million) Figure 32. Japan Hepatoma Cell Targeted Drug Market Size YoY Growth (2017-2028) & (US$ Million) Figure 33. South Korea Hepatoma Cell Targeted Drug Market Size YoY Growth (2017-2028) & (US$ Million) Figure 34. Southeast Asia Hepatoma Cell Targeted Drug Market Size YoY Growth (2017-2028) & (US$ Million) Figure 35. India Hepatoma Cell Targeted Drug Market Size YoY Growth (2017-2028) & (US$ Million) Figure 36. Australia Hepatoma Cell Targeted Drug Market Size YoY Growth (2017-2028) & (US$ Million) Figure 37. Latin America Hepatoma Cell Targeted Drug Market Size YoY Growth (2017-2028) & (US$ Million) Figure 38. Latin America Hepatoma Cell Targeted Drug Market Share by Country (2017-2028) Figure 39. Mexico Hepatoma Cell Targeted Drug Market Size YoY Growth (2017-2028) & (US$ Million) Figure 40. Brazil Hepatoma Cell Targeted Drug Market Size YoY Growth (2017-2028) & (US$ Million) Figure 41. Middle East & Africa Hepatoma Cell Targeted Drug Market Size YoY Growth (2017-2028) & (US$ Million) Figure 42. Middle East & Africa Hepatoma Cell Targeted Drug Market Share by Country (2017-2028) Figure 43. Turkey Hepatoma Cell Targeted Drug Market Size YoY Growth (2017-2028) & (US$ Million) Figure 44. Saudi Arabia Hepatoma Cell Targeted Drug Market Size YoY Growth (2017-2028) & (US$ Million) Figure 45. Bayer Revenue Growth Rate in Hepatoma Cell Targeted Drug Business (2017-2022) Figure 46. Eisai Revenue Growth Rate in Hepatoma Cell Targeted Drug Business (2017-2022) Figure 47. Zelgen Revenue Growth Rate in Hepatoma Cell Targeted Drug Business (2017-2022) Figure 48. Cipla Revenue Growth Rate in Hepatoma Cell Targeted Drug Business (2017-2022) Figure 49. Natco Pharma Revenue Growth Rate in Hepatoma Cell Targeted Drug Business (2017-2022) Figure 50. BEACON Pharma Revenue Growth Rate in Hepatoma Cell Targeted Drug Business (2017-2022) Figure 51. Jiangxi Shanxiang Revenue Growth Rate in Hepatoma Cell Targeted Drug Business (2017-2022) Figure 52. Yao Pharma Revenue Growth Rate in Hepatoma Cell Targeted Drug Business (2017-2022) Figure 53. CSPC Revenue Growth Rate in Hepatoma Cell Targeted Drug Business (2017-2022) Figure 54. CHIATAI Tianqing Revenue Growth Rate in Hepatoma Cell Targeted Drug Business (2017-2022) Figure 55. Simcere Revenue Growth Rate in Hepatoma Cell Targeted Drug Business (2017-2022) Figure 56. Bottom-up and Top-down Approaches for This Report Figure 57. Data Triangulation Figure 58. Key Executives Interviewed

Bayer Eisai Zelgen Cipla Natco Pharma BEACON Pharma Jiangxi Shanxiang Yao Pharma CSPC CHIATAI Tianqing Simcere